Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept

被引：3

作者：

Arita, Yuki ^{[1
]}

Taguchi, Hiroaki ^{[2
]}

Kobayashi, Mari ^{[1
]}

Tono, Toshihiro ^{[2
]}

Ohsone, Yasuo ^{[2
]}

Okano, Yutaka ^{[2
]}

机构：

[1] Kawasaki Municipal Kawasaki Hosp, Dept Internal Med, Kawasaki, Kanagawa, Japan

[2] Kawasaki Municipal Kawasaki Hosp, Ctr Arthrit & Rheumat Dis, Kawasaki, Kanagawa, Japan

来源：

MODERN RHEUMATOLOGY | 2018年 / 28卷 / 06期

关键词：

Disease-modifying antirheumatic drug; Iguratimod; Pneumocystis jirovecii pneumonia; Rheumatoid arthritis; ANTIRHEUMATIC DRUG; DOUBLE-BLIND; THERAPY; EFFICACY;

D O I：

10.1080/14397595.2016.1181026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 66-year-old woman who had rheumatoid arthritis and underwent a long-term treatment with methotrexate and etanercept developed Pneumocystis jirovecii pneumonia (PCP) 3 months after iguratimod add-on. Although most rheumatologists might have the impression that iguratimod has less toxicity and immunosuppressive effect compared with methotrexate and biologic disease-modifying antirheumatic drugs, this case suggests that iguratimod may increase the risk of PCP, especially in combination with other drugs.

引用

页码：1041 / 1043

页数：3

共 31 条

[31] Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Atsumi, Tatsuya
Tanaka, Yoshiya
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Yamanaka, Hisashi
Ishiguro, Naoki
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Yasuda, Shinsuke
Yamanishi, Yuji
Kita, Yasuhiko
Matsubara, Tsukasa
Iwamoto, Masahiro
Shoji, Toshiharu
Togo, Osamu
Okada, Toshiyuki
van der Heijde, Desiree
Miyasaka, Nobuyuki
Koike, Takao
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1348 - 1356

← 1 2 3 4 →